Advertisement

Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature

      Abstract

      Background

      Tetrabenazine (TBZ) is a monoamine storage inhibitor that was first introduced in the 1970s for the management of hyperkinetic movement disorders. Despite acceptance and usage worldwide, TBZ was only recently approved in the United States for the treatment of Huntington chorea. This review focuses on the use of TBZ in various hyperkinetic movement disorders, which are considered “rare” or “orphan” diseases, to help practitioners better understand its clinical role and use.

      Objective

      This review describes the clinical efficacy and tolerability of TBZ in the management of dystonia, Huntington chorea, tardive dyskinesia (TDk), and tic disorders.

      Methods

      A Cochrane Library, EMBASE, MedlinePlus, PubMed, and clinical trials database search (up to May 2012) was conducted to identify articles and studies using the subject terms tetrabenazine, Huntington disease, dystonia, tardive dyskinesia, Tourette, tics, and hyperkinetic movement. Only English-language articles were reviewed.

      Results

      TBZ variably undergoes extensive first-pass metabolism to active metabolites, some of which are metabolized by the cytochrome P450 2D6 isozyme. Pharmacology studies demonstrate that TBZ reversibly inhibits the activity of vesicular monoamine transporter 2, resulting in depletion of central dopamine. For management of dystonias, 1 of 3 small prospective blinded studies and 4 of 5 retrospective studies reported clinical benefit with TBZ use in pediatrics and adults. For Huntington chorea, 2 randomized, double-blind, placebo-controlled studies along with open-label studies demonstrate the effectiveness of TBZ in adults. For TDk, 9 of 11 studies (prospective controlled and retrospective) reported positive benefit. For Gilles de la Tourette syndrome, 9 of 11 studies (prospective controlled and retrospective) reported positive benefit on motor and phonic tics in pediatric and adult patients. Overall, adverse effects are dose and age related and include depression, fatigue, parkinsonism, and somnolence.

      Conclusions

      TBZ is an effective oral therapy for chorea of Huntington disease and may be considered as an alternative agent for the management of dystonia, TDk, and tic disorders (these latter 3 conditions are off-label uses in the United States). The drug possesses an acceptable tolerability profile and has been used in pediatric and adult populations.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Reich S.G.
        Pearls: hyperkinetic movement disorders.
        Semin Neurol. 2010; 30: 15-22
        • National Organization for Rare Disorders
        Rare disease database.
        (Accessed May 10, 2012)
        • Centonze D.
        • Bernardi G.
        • Koch G.
        Mechanisms of disease: basic-research-driven investigations in humans—the case of hyperkinetic disorders.
        Nat Clin Pract Neurol. 2007; 3: 572-580
        • Mestre T.
        • Ferreira J.
        • Coelho M.M.
        • et al.
        Therapeutic interventions for symptomatic treatment in Huntington's disease.
        Cochrane Database Systematic Rev. 2009; (CD006456)
        • Soares-Weiser K.
        • Fernandez H.H.
        Tardive dyskinesia.
        Semin Neurol. 2007; 27: 159-169
        • Cloud L.J.
        • Jinnah H.A.
        Treatment strategies for dystonia.
        Expert Opin Pharmacother. 2010; 11: 5-15
        • Huys D.
        • Hardenacke K.
        • Poppe P.
        • et al.
        Update on the role of antipsychotics in the treatment of Tourette syndrome.
        Neuropsychiatr Dis Treat. 2012; 8: 95-104
        • Fasano A.
        • Bentivoglio A.R.
        Tetrabenazine.
        Expert Opin Pharmacother. 2009; 10: 2883-2896
        • Scott L.J.
        Tetrabenazine: for chorea associated with Huntington's disease.
        CNS Drugs. 2011; 25: 1073-1078
        • Jankovic J.
        • Clarence-Smith K.
        Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders.
        Expert Rev Neurother. 2011; 11: 1509-1523
        • de Tommaso M.
        • Serpino C.
        • Sciruicchio V.
        Management of Huntington's disease: role of tetrabenazine.
        Ther Clin Risk Manag. 2011; 7: 123-129
        • Frank S.
        Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.
        Neuropsychiatr Dis Treat. 2010; 6: 657-665
        • Poon L.H.
        • Kang G.A.
        • Lee A.J.
        Role of tetrabenazine for Huntington's disease-associated chorea.
        Ann Pharmacother. 2010; 44: 1080-1089
        • Leung J.G.
        • Breden E.L.
        Tetrabenazine for the treatment of tardive dyskinesia.
        Ann Pharmacother. 2011; 45: 525-531
        • Guay D.R.
        Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
        Am J Geriatr Pharmacother. 2010; 8: 331-373
        • Roberts M.S.
        • McLean S.
        • Millingen K.S.
        • Galloway H.M.
        The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders.
        Eur J Clin Pharmacol. 1986; 29: 703-708
        • Yao Z.
        • Wei X.
        • Wu X.
        • et al.
        Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors.
        Eur J Med Chem. 2011; 46: 1841-1848
        • Mehvar R.
        • Jamali F.
        • Watson M.W.
        • et al.
        Pharmacokinetics of tetrabenazine and its major metabolite in man and rat.
        Drug Metab Dispos. 1987; 15: 250-255
        • Kanner B.I.
        • Schuldiner S.
        Mechanism of storage and transport of neurotransmitters.
        CRC Crit Rev Biochem. 1987; 22: 1-38
        • Johnson R.G.
        Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport.
        Physiol Rev. 1988; 68: 232-307
        • Wimalasena K.
        Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry.
        Med Res Rev. 2011; 31: 483-519
        • Kilbourn M.R.
        • DaSilva J.N.
        • Frey K.A.
        • et al.
        In vivo imaging of vesicular monoamine transporters in human brain using [11C]tetrabenazine and positron emission tomography.
        J Neurochem. 1993; 60: 2315-2318
        • Vander Borght T.M.
        • Kilbourn M.R.
        • Koeppe R.A.
        • et al.
        In vivo imaging of the brain vesicular monoamine transporter.
        J Nucl Med. 1995; 36: 2252-2260
        • Koeppe R.A.
        • Frey K.A.
        • Kuhl D.E.
        • et al.
        Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine.
        J Cereb Blood Flow Metab. 1999; 19: 1376-1384
        • Koeppe R.A.
        • Frey K.A.
        • Kume A.
        • et al.
        Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-alpha-[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography.
        J Cereb Blood Flow Metab. 1997; 17: 919-931
        • Pearson S.J.
        • Reynolds G.P.
        Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease.
        Neuropharmacology. 1988; 27: 717-719
        • Porta M.
        • Sassi M.
        • Cavallazzi M.
        • et al.
        Tourette's syndrome and role of tetrabenazine.
        Clin Drug Invest. 2008; 28: 443-459
        • Pletscher A.
        • Brossi A.
        • Gey K.F.
        Benzoquinolizine derivatives: a new class of monamine decreasing drugs with psychotropic action.
        Rev Neurobiol. 1962; 4: 275-306
        • Fahn S.
        Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.
        Adv Neurol. 1983; 37: 267-276
        • Cardoso F.
        • Seppi K.
        • Mair K.J.
        • et al.
        Seminar on choreas.
        Lancet Neurol. 2006; 5: 589-602
        • Leigh R.J.
        • Newman S.A.
        • Folstein S.E.
        • et al.
        Abnormal ocular motor control in Huntington's disease.
        Neurology. 1983; 33: 1268-1275
        • Carella F.
        • Scaioli V.
        • Ciano C.
        • et al.
        Adult onset myoclonic Huntington's disease.
        Mov Disord. 1993; 8: 201-205
        • Jankovic J.
        • Ashizawa T.
        Tourettism associated with Huntington's disease.
        Mov Disord. 1995; 10: 103-105
        • Tan E.K.
        • Jankovic J.
        • Ondo W.
        Bruxism in Huntington's disease.
        Mov Disord. 2000; 15: 171-173
        • Louis E.D.
        • Lee P.
        • Quinn L.
        • et al.
        Dystonia in Huntington's disease: prevalence and clinical characteristics.
        Mov Disord. 1999; 14: 95-101
        • Grimbergen Y.A.
        • Knol M.J.
        • Bloem B.R.
        • et al.
        Falls and gait disturbances in Huntington's disease.
        Mov Disord. 2008; 23: 970-976
        • Caine E.D.
        • Shoulson I.
        Psychiatric syndromes in Huntington's disease.
        Am J Psychiatry. 1983; 140: 728-733
        • Schoenfeld M.
        • Myers R.H.
        • Cupples L.A.
        • et al.
        Increased rate of suicide among patients with Huntington's disease.
        J Neurol Neurosurg Psychiatry. 1984; 47: 1283-1287
        • Mendez M.F.
        Huntington's disease: update and review of neuropsychiatric aspects.
        Int J Psychiatry Med. 1994; 24: 189-208
        • Shiwach R.
        Psychopathology in Huntington's disease patients.
        Acta Psychiatr Scand. 1994; 90: 241-246
        • Rosenblatt A.
        • Leroi I.
        Neuropsychiatry of Huntington's disease and other basal ganglia disorders.
        Psychosomatics. 2000; 41: 24-30
        • Lawrence A.D.
        • Sahakian B.J.
        • Hodges J.R.
        • et al.
        Executive and mnemonic functions in early Huntington's disease.
        Brain. 1996; 119: 1633-1645
        • Kirkwood S.C.
        • Su J.L.
        • Conneally P.
        • et al.
        Progression of symptoms in the early and middle stages of Huntington disease.
        Arch Neurol. 2001; 58: 273-278
        • Ho A.K.
        • Sahakian B.J.
        • Brown R.G.
        • et al.
        Profile of cognitive progression in early Huntington's disease.
        Neurology. 2003; 61: 1702-1706
        • Lanska D.J.
        • Lanska M.J.
        • Lavine L.
        • et al.
        Conditions associated with Huntington's disease at death.
        Arch Neurol. 1988; 45: 878-880
        • Sorensen S.A.
        • Fenger K.
        Causes of death in patients with Huntington's disease and in unaffected first degree relatives.
        J Med Genet. 1992; 29: 911-914
        • Huntington's Disease Collaborative Research Group
        A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.
        Cell. 1993; 72: 971-983
        • Rubinsztein D.C.
        • Leggo J.
        • Coles R.
        • et al.
        Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats.
        Am J Hum Genet. 1996; 59: 16-22
        • Ranen N.G.
        • Stine O.C.
        • Abbott M.H.
        • et al.
        Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease.
        Am J Hum Genet. 1995; 57: 593-602
        • Laccone F.
        • Engel U.
        • Holinski-Feder E.
        • et al.
        DNA analysis of Huntington's disease: five years of experience in Germany, Austria, and Switzerland.
        Neurology. 1999; 53: 801-806
        • Kenney C.
        • Powell S.
        • Jankovic J.
        Autopsy-proven Huntington's disease with 29 trinucleotide repeats.
        Mov Disord. 2007; 22: 127-130
        • Ferrante R.J.
        • Kowall N.W.
        • Beal M.F.
        • et al.
        Selective sparing of a class of striatal neurons in Huntington's disease.
        Science. 1985; 230: 561-563
        • Hedreen J.C.
        • Peyser C.E.
        • Folstein S.E.
        • et al.
        Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease.
        Neurosci Lett. 1991; 133: 257-261
        • Margolis R.L.
        • Ross C.A.
        Diagnosis of Huntington disease.
        Clin Chem. 2003; 49: 1726-1732
        • Truant R.
        • Atwal R.S.
        • Desmond C.
        • et al.
        Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases.
        FEBS J. 2008; 275: 4252-4262
        • Bonelli R.M.
        • Wennig G.K.
        Pharmacological management of Huntington's disease: an evidence based review.
        Curr Pharm Des. 2006; 12: 2701-2720
        • Bonelli R.M.
        • Hofmann P.
        A systematic review of the treatment studies in Huntington's disease since 1990.
        Expert Opin Pharmacother. 2007; 8: 141-153
        • Frank S.
        • Jankovic J.
        Advances in the pharmacological management of Huntington's disease.
        Drugs. 2010; 70: 561-571
        • Huntington Study Group
        Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial.
        Neurology. 2006; 66: 366-372
        • Frank S.
        • Ondo W.
        • Fahn S.
        • et al.
        A study of chorea after tetrabenazine withdrawal in patients with Huntington's disease.
        Clin Neuropharmacol. 2008; 31: 127-133
        • Frank S.
        Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study.
        BMC Neurol. 2009; 9: 62
        • Brusa L.
        • Orlacchio A.
        • Moschella V.
        • et al.
        Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine.
        Mov Disord. 2009; 24: 126-129
        • Kenney C.
        • Hunter C.
        • Davidson A.
        • Jankovic J.
        Short-term effects of tetrabenazine on chorea associated with Huntington's disease.
        Mov Disord. 2007; 22: 10-13
        • Fasano A.
        • Cadeddu F.
        • Guidubaldi A.
        • et al.
        The long-term effect of tetrabenazine in the management of Huntington's disease: observational study.
        Clin Neuropharmacol. 2008; 31: 313-318
        • Kenney C.J.
        • Hunter C.
        • Jankovic J.
        Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.
        Mov Disord. 2007; 22: 193-197
        • Fekete R.
        • Davidson A.
        • Ondo W.G.
        • et al.
        Effect of tetrabenazine on computerized dynamic posturography in Huntington disease patients.
        Parkinsonism Relat Disord. 2012 May 21; ([Epub ahead of print])
        • Snaith A.
        • Wade D.
        Dystonia.
        Clin Evid (Online). 2011; 2011 (pii: 1211)
        • Swash M.
        • Roberts A.H.
        • Zakko H.
        • et al.
        Treatment of involuntary movement disorders with tetrabenazine.
        J Neurol Neurosurg Psychiatry. 1972; 35: 186-191
        • Asher S.W.
        • Aminoff M.J.
        Tetrabenazine and movement disorders.
        Neurology. 1981; 31: 1051-1054
        • Jankovic J.
        Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study.
        Ann Neurol. 1982; 11: 41-47
        • Marsden C.D.
        • Marion M.H.
        • Quinn N.
        The treatment of severe dystonia in children and adults.
        J Neurol Neurosurg Psychiatry. 1984; 47: 1166-1173
        • Jankovic J.
        • Orman J.
        Tetrabenazine therapy of dystonia, chorea, tics and other dyskinesia.
        Neurology. 1988; 38: 391-394
        • Jankovic J.
        • Beach J.
        Long-term effects of tetrabenazine in hyperkinetic movement disorders.
        Neurology. 1997; 48: 358-362
        • Paleacu D.
        • Giladi N.
        • Moore O.
        • et al.
        Tetrabenazine treatment in movement disorders.
        Clin Neuropharmacol. 2004; 27: 230-233
        • Chen J.J.
        • Swope D.M.
        Movement disorders.
        in: Tisdale J. Miller D. Drug-Induced Diseases: Prevention, Detection, and Management. 2nd ed. American Society of Health-System Pharmacists, Bethesda, Md2010: 211-235
        • Godwin-Austen R.B.
        • Clark T.
        Persistent phenothiazine dyskinesia treated with tetrabenazine.
        Br Med J. 1971; 4: 25-26
        • Kazamatsuri H.
        • Chien C.P.
        • Cole J.O.
        Treatment of tardive dyskinesia: clinical efficacy of a dopamine-depleting agent, tetrabenazine.
        Arch Gen Psychiatry. 1972; 27: 95-99
        • Kazamatsuri H.
        • Chien C.P.
        • Cole J.O.
        Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine.
        Am J Psychiatry. 1973; 130: 479-483
        • Watson M.W.
        • Skelton D.
        • Jamali F.
        Treatment of tardive dyskinesia: preliminary report on use of tetrabenazine.
        Can J Psychiatry. 1988; 33: 11-13
        • Ondo W.G.
        • Hanna P.A.
        • Jankovic J.
        Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol.
        Am J Psychiatry. 1999; 156: 1279-1281
      1. (ClinicalTrials.gov)
        NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder.
        (Accessed June 21, 2012)
        • Steeves T.D.
        • Fox S.H.
        Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome.
        Prog Brain Res. 2008; 172: 495-513
        • Sweet R.D.
        • Bruun R.
        • Shapiro E.
        • et al.
        Presynaptic catecholamine antagonists as treatment for Tourette syndrome.
        Arch Gen Psychiatry. 1974; 31: 857-861
        • Jankovic J.
        • Glaze D.G.
        • Frost Jr, J.D.
        Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome.
        Neurology. 1984; 34: 688-692
        • Jankovic J.
        • Rohaidy H.
        Motor, behavioral and pharmacologic findings in Tourette's syndrome.
        Can J Neurol Sci. 1987; 14: 541-546
        • Vuong K.
        • Hunter C.B.
        • Mejia N.
        • et al.
        Safety and efficacy of tetrabenazine in childhood hyperkinetic movement disorders.
        Mov Disord. 2004; 19 (Abstract): S422
        • Jain S.
        • Greene P.E.
        • Frucht S.J.
        Tetrabenazine therapy of pediatric hyperkinetic movement disorders.
        Mov Disord. 2006; 21: 1966-1972
        • Kenney C.J.
        • Hunter C.B.
        • Mejia N.
        • Jankovic J.
        Tetrabenazine in the treatment of Tourette's syndrome.
        J Ped Neurol. 2007; 5: 9-13
        • Jankovic J.
        • Pardo R.
        Segmental myoclonus.
        Arch Neurol. 1986; 43: 1025-1031
        • Sitburana O.
        • Ondo W.G.
        Tetrabenazine (TBZ) for hyperglycemic-induced hemichorea-hemiballismus (HIHH).
        Mov Disord. 2006; 21: 2023-2025
      2. Ondo WG. Tetrabenazine treatment for stereotypies and tics associated with dementia. J Neuropsych Clin Neurosci. In press.

        • Mateo D.
        • Muñoz-Blanco J.L.
        • Giménez-Roldán S.
        Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease.
        Clin Neuropharmacol. 1992; 15: 63-68
        • Ossemann M.
        • Sindic C.J.
        • Laterre C.
        Tetrabenazine as a cause of neuroleptic malignant syndrome.
        Mov Disord. 1996; 11: 95
        • Petzinger G.M.
        • Bressman S.B.
        A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment.
        Mov Disord. 1997; 12: 246-248
        • Stevens E.
        • Roman A.
        • Houa M.
        • et al.
        Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia.
        Intensive Care Med. 1998; 24: 369-371
        • Lundbeck Inc.
        US prescribing information: Xenazine (tetrabenazine) tablets.
        (Accessed May 10, 2012)
        • Kenney C.
        • Hunter C.
        • Mejia N.
        • Jankovic J.
        Is history of depression a contraindication to treatment with tetrabenazine.
        Clin Neuropharmacol. 2006; 29: 259-260
        • Dorsey R.
        • Biglan K.
        • Eberly S.
        • et al.
        Use of tetrabenazine in Huntington disease patients on antidepressants or with advanced disease: results from the TETRA-HD study.
        PLoS Curr. 2011; 3: RRN1283
        • Xenazine
        RED BOOK Online. Micromedex 2.0.
        ThomsonReuters, New York, NY2012